Clofibrate (Atromid-S - ICI) has been used for almost 20 years in the management of patients with hyperlipidaemia. In this time it has been possible to assess the long-term risks of the drug and its place in primary and secondary prevention of coronary heart disease. These factors, and the introduction of alternative therapy, have prompted this article.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.